Representational image
Piramal Pharma aims to achieve $2 billion in revenue by 2030, driven by its three key segments: contract development and manufacturing (CDMO), complex hospital generics, and consumer healthcare.
A major factor in the brand’s CDMO business is the company’s capacity to serve customers globally, particularly in both the East and West, without relying on China.
Currently, the CDMO segment accounts for 58% of Piramal Pharma’s revenue. For the…
Read More…
Source: https://chemindigest.com/piramal-pharma-eyes-2-billion-revenue-target-by-2030/